A Silicon Valley drugmaker focused on anti-aging treatments has raised $116 million from investors to support the development of medicines designed to help people stay healthy as they grow older. Unity Biotechnology said Thursday that it attracted support for the Series B funding round from a slew of traditional biotech investors including Fidelity Management & Research Co., Arch Venture Partners, Partner Funds Management and Venrock.